- Evan Austin, MD, PhD
- Congress Reports, Comorbidities, Quality of Life, Research, Types of Psoriasis
The 2024 Society for Investigative Dermatology (SID) Annual Meeting was held in Dallas, Texas, from May 14 to 18. Experts and thought leaders in basic science, translational, and clinical psoriasis research convened to discuss advances in clinical care. The SID has over 400 members from 32 countries. More than 1000 abstracts were accepted and presented from members and non-members. Over the last decade, biochemical knowledge and treatment of psoriasis have expanded at a fantastic pace. FDA-approved biologics and small molecule drugs, including inhibitors/modulators of TNF, IL-17/12/23, JAK, PDE-4, TYK2, and the aryl hydrocarbon receptor, have greatly improved patient outcomes, quality of life, and care for those affected by psoriasis. Additionally, numerous novel drugs affecting new pathways are in the pipeline. As a result of these successes, multiple researchers examined how the treatment of psoriasis improves patient well-being and how we can reach underserved patients.
The following report covers 21 presentations on psoriasis, including the International Psoriasis (IPC) Council Symposium: Advances in Technologies and Analytics in Understanding Psoriasis Pathophysiology. Download the full SID Congress Report or read on for highlights.
IPC SYMPOSIUM: ADVANCES IN TECHNOLOGIES AND ANALYTICS IN UNDERSTANDING PSORIASIS PATHOPHYSIOLOGY
Part 1: Current Insights and Future Directions
- Wilson Liao, MD, IPC Councilor, presented background on The Microbiome and Psoriasis and shared how the gut microbiome may influence psoriasis severity and comorbidities, including psoriatic arthritis, and might predict treatment responses.
- Emanual Maverakis, MD, shared the functional roles of T-cell receptor segments in different cell types and their contributions to psoriasis pathogenesis in his presentation titled TCR Analysis Using Genomics Data.
- Alex Tsoi, MD, PhD, IPC Councilor, presented Statistical Genomics and Multi-omic Approaches in Advancing Genetic Research, which aimed to help bridge the gap between genetic data and clinical applications, enhancing our understanding of psoriasis and improving personalized treatment strategies.
- Looking Towards Personalized Diagnosis and Therapy, Curdin Conrad, MD, IPC Councilor, discussed potential applications of personalized approaches in treating different forms of psoriasis.
Part 2: Poster Presentations
- KatIyn Richardson presented Granzyme K Promotes IL-23 Secretion and Keratinocyte Proliferation in Psoriasis, highlighting GzmK as a promising therapeutic target for psoriasis.
- The Prevalence and Association of Psoriasis in Patients with Seborrheic Dermatitis: A Systematic Review and Meta-Analysis was presented by Christy Chang, who shared that the frequency of co-occurring SD and psoriasis in adults is low.
- Comparing Itch in Psoriasis, Atopic Dermatitis, and Chronic Idiopathic Urticaria: A Meta-Analysis showed that psoriasis patients had similar baseline itch scores to CIU patients described by Judy Gao, MD. Suggesting an itch could be an early indicator of disease flares and that treatment should begin at the first sign of itch rather than a rash.
- Rudolf Schopf, MD, presented Periodontitis as a Risk Factor for Psoriasis as psoriasis patients exhibit a higher risk for periodontitis, suggesting that periodontal disease should be considered a comorbidity.
- Peter Lipsky, MD, delivered the presentation on behalf of Sneha Shrotri titled Heterogeneity of Psoriatic Skin Lesions Identified by a Novel Transcriptomic Based Psoriasis Cell and Immune Score which was able to differentiate between lesional and non-lesional skin and may be a method to grade the molecular severity of psoriatic skin and monitor changes with therapy.
- Ling-Juan Zhang, PhD, discussed the Dual Role of Dermal Adipogenesis in Regulating Neutrophil Activation and Regression.
- Britta De Pessemier presented a Comparative Whole Metagenome Sequencing Analysis in Psoriasis Capitis Patients and Healthy Individuals, suggesting the microbiome’s significant role in psoriasis pathology.
- Mehdi Rashighi, MD, shared the presentation on behalf of Khashir Abhashari, MD, MPH, titled Comparative Multi-omics Study of Inflammatory Skin Diseases Uncover Novel Disease-Specific Heterogeneity in Skin Resident Myeloid Cells, highlighting the importance of disease-specific immune cell populations in developing targeted therapies.
SID CONGRESS PRESENTATIONS
- Lily Guo highlighted research on the associations between psoriasis and pulmonary disease in the presentation titled Scaling Down Lung Disease: COPD Complications in Psoriasis Patients.
- In the presentation, Protective Effects of Apremilast Against Cardiovascular Disease in Psoriasis and the Role of Monocytes, Dr. Alison Treichel, IPC Fellow 2024, discussed how patients treated with apremilast had decreased risks of heart failure, myocardial infarction, cerebral vascular disease, deep vein thrombosis, and hypertension compared to topical corticosteroids.
- William Song discussed demographic data Identifying Disparities in Phototherapy Dosing and Research Participation Among Patients with Psoriasis by Race, Ethnicity, and Skin Phototype: Findings from the Light Treatment Effectiveness Study, which compared office and home phototherapy for psoriasis.
- George Gonda presented Perceptions of Psoriasis Patients with BSA ≤3% Not Being in Remission: Insights from the National Psoriasis Foundation Annual Survey where patients cited the involvement of sensitive areas, long-term biologic use, and continued symptoms as important factors in persistent disease activity despite low BSA.
- Jacky Chen shared the Effects of Systemic Biologic Treatments on Cardiovascular Outcomes Among Patients with Psoriasis with a single biologic agent compared to topical corticosteroids.
- Dr. Junko Takeshita, IPC Councilor, shared insights and obstacles in Paving a Path to Equity in Psoriasis and provided personal accounts of how disparities affect clinical interactions.
- Patients shared that a lack of trust, travel expense, distance, safety, and scarring were factors limiting participation in clinical trials in Veda Nagubandi’s presentation, Identifying Barriers and Facilitators to Participating in Clinical Research Among Racial and Ethnic Minoritized Adults with Psoriasis.
- Dr. Raghunath Chatterjee presented a potential negative feedback mechanism in psoriasis the presentation in which upregulation of miR-7-5p was found to have anti-proliferative effects on keratinocytes in the presentation Compensatory Role of Interleukin-17A in Regulating the Proliferation of Epidermal Keratinocytes in Psoriasis.
- Kathryn Haran discussed unique inheritance and prognosis in the presentation titled Predominantly Genital and Inverse Psoriasis (PGIP): Description of a Unique Psoriasis Subtype.
For those seeking a more detailed understanding of these sessions, we recommend downloading the complete 2024 SID Congress Report.
